U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07431073) titled 'Immunotherapy Master Trial for Advanced Cancers' on Jan. 13.
Brief Summary: Over the past decade, cancer immunotherapy has profoundly transformed oncology by harnessing the patient's immune system to target tumors. These therapies have demonstrated the potential for durable responses and, in some cases, long-term remission or cure. However, despite these advances, only approximately 20-30% of patients derive significant clinical benefit from current immunotherapies. In parallel, investment in oncology drug development continues to grow, with global spending projected to reach $307 billion by 2026. Yet, the overall failure rate in on...